News >

FDA Approves Isatuximab for Relapsed/Refractory Myeloma

Gina Columbus @ginacolumbusonc
Published: Monday, Mar 02, 2020

The FDA has approved isatuximab-irfc (Sarclisa) for use in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of adult patients with multiple myeloma who have received ≥2 prior therapies, including lenalidomide and a proteasome inhibitor.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication